
Pharmacally
MASH
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in MASH
Clinical TrialsMerck Reports Positive Phase 2b Results for Efinopegdutide in MASHMerck’s investigational GLP-1/glucagon receptor co-agonist efinopegdutide achieved its primary endpoint in a Phase 2b MASH trial, with 63% resolution at the 7 mg dose versus 13% with placebo.…Fact-Checked
Health TidingsALG-055009 Cuts Liver Fat in MASH Phase 2a TrialAligos Therapeutics’ oral THR-β agonist ALG-055009 significantly reduced liver fat in adults with non-cirrhotic MASH in the phase 2a HERALD trial.Fact-Checked
Health TidingsSaroglitazar Hits Primary Endpoint in Zydus’ Phase II(b) MASH TrialZydus Lifesciences reported that saroglitazar magnesium met the primary endpoint in the global Phase IIb EVIDENCES-X trial in patients with MASH and fibrosis, with a 26.5% treatment difference…Fact-Checked
Mergers & AcquisitionsArrowhead Takes Aim at MASH Genetics with Madrigal Licensing DealArrowhead Pharmaceuticals and Madrigal Pharmaceuticals enter a global deal for ARO-PNPLA3, an investigational RNAi therapy targeting PNPLA3 mutations in MASH, supported by Phase 1 data showing significant liver…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.